Hemifacial spasm

Signs and symptoms

The first sign of hemifacial spasm is typically muscle movement in the patient's eyelid and around the eye. It can vary in intensity.

Causes

Three theories exist to explain the facial nerve dysfunction found in hemifacial spasm. The first proposed theory is ephaptic transmission, which is electrical activity crossing from one demyelinated neuron to another resulting in a false synapse. The second theory involves abnormal activity of axons at the facial nerve root end zone secondary to compressive damage/demyelination.

The third theory or "Kindling theory" involves increased excitability of the facial nerve nucleus due to feedback from a damaged facial nerve.

It is generally accepted as compression of the facial nerve by vessels of the posterior circulation. Hemifacial spasm is much more common in some Asian populations.

Several families with hemifacial spasm have been reported, suggesting a genetic etiology or predisposition in some cases. There appears to be an autosomal dominant pattern of inheritance in these families with low penetrance, and except for a younger age at onset, the clinical features overlap with the idiopathic cases. Evaluation of single-nucleotide polymorphisms in genes related to vascular change causing compression of blood vessels did not show an association with hemifacial spasm. Clarifying the role of genetic susceptibility in hemifacial spasm may help to better understand the pathogenesis of this disease.

Diagnosis

There are several tests available to diagnose a case of hemifacial spasm. Diagnosis begins with a complete neurological exam, including an electromyography (EMG: a test that measures and records electrical activity generated in muscle at rest and in response to muscle contraction), magnetic resonance imaging (MRI: a test that uses magnetic waves to make pictures of structures inside the head), computed tomography (CT scan: a type of x-ray that uses a computer to make pictures of structures inside the head), and angiography (an x-ray exam of the blood vessels when they are filled with a contrast material).

Studies have shown that the most effective method of hemifacial spasm screening is MRI. In one study, only 25% of the CT scans showed the abnormality in hemifacial spasm patients, whilst more than half of the MRI imaging demonstrated a vascular anomaly. MRI imaging is recommended as the initial screening procedure in the assessment of patients with hemifacial spasm.

Prevention

There is no known way to prevent hemifacial spasm.

Treatments

Mild cases of hemifacial spasm may be managed with sedation or carbamazepine (an anticonvulsant drug). Microsurgical decompression and botulinum toxin injections are the current main treatments used for hemifacial spasm.

Microvascular decompression

Microvascular decompression appears to be the most popular surgical treatment at present. Microvascular decompression relieves pressure on the facial nerve, which is the cause of most hemifacial spasm cases. Excellent to good results are reported in 80% or more cases with a 10% recurrence rate. In the present series approximately 10% had previously failed surgery. Serious complications can follow microsurgical decompressive operations, even when performed by experienced surgeons. These include cerebellar haematoma or swelling, brainstem infarction (blood vessel of the brain stem blocked), cerebral infarction (ischemic stroke resulting from a disturbance in the blood vessels supplying blood to the brain), subdural haematoma and intracerebral infarction (blockage of blood flow to the brain). Death or permanent disability (hearing loss) can occur in 2% of patients of hemifacial spasm.

Botulinum toxin

Observational data from studies (the updated review in 2020 did not find any randomized controlled trials) indicates that botulinum toxin is safe and effective in the treatment of hemifacial spasm with success rates of between 76–100%. The injections are administered as an outpatient or office procedure. Although side effects do occur, these are never permanent. Repeated injections over the years remain highly effective. Whilst the toxin is expensive, the cost of even prolonged courses of injections compares favourably with the cost of surgery. Patients with HFS should be offered a number of treatment options. Sometimes as a temporary measure, medical treatment can be offered to patients with very mild cases or those who are reluctant to have surgery or botulinum toxin injections. In young and fit patients, microsurgical decompression and botulinum injections should be discussed as alternative procedures. In the majority of cases, and especially in the elderly and the unfit, botulinum toxin injection is the treatment of first choice. Imaging procedures should be done in all unusual cases of hemifacial spasm and when surgery is contemplated.

Patients with hemifacial spasm were shown to have decreased sweating after botulinum toxin injections. This was first observed in 1993 by Khalaf Bushara and David Park in the first demonstration of nonmuscular use of BTX-A. Bushara further showed the efficacy of botulinum toxin in treating hyperhidrosis (excessive sweating). BTX-A was later approved for the treatment of excessive underarm sweating. This is technically known as severe primary axillary hyperhidrosis – excessive underarm sweating with an unknown cause which cannot be managed by topical agents (see focal hyperhidrosis).

Epidemiology

The incidence of hemifacial spasm is approximately 0.8 per 100,000 persons. Hemifacial spasm is more prevalent among females over 40 years of age. The estimated prevalence for women is 14.5 per 100,000 and 7.4 per 100,000 in men. Prevalence for hemifacial spasm increases with age, reaching 39.7 per 100,000 for those aged 70 years and older. One study divided 214 hemifacial patients based on the cause of the disease: primary hemifacial spasm, where the patients had a compression in the facial nerve at the end of the brainstem; and secondary hemifacial spasm, where the patients had peripheral facial palsy or nerve lesion due to tumors, demyelination, trauma or infection. The study found that 77% of cases were primary and 23% secondary. The study also found that the two sets of patients shared a similar age at onset, male to female ratios, and similar affected side. In another study of 2050 patients who had presented with hemifacial spasm between 1986 and 2009, only nine cases were caused by a cerebellopontine angle syndrome, an incidence of 0.44%.

History

The earliest descriptions about hemifacial spasm is by Shultze in 1875 and Gowers in 1899. The etiology of hemifacial spasm and location of the abnormality have been debated for more than a century. Surgical treatment for hemifacial spasm in the early 20th century included neurolysis (destruction of nerve tissue), stretching the facial nerve (seventh cranial nerve), and high-pressure irrigation of the nerve with lactate ringer's solution. The medical regimens of that time involved injection of the nerve with ethanol, electrical stimulation, application of toxic compounds (nitrate of silver, zinc, arsenic, bromides) as well as medications such as Dilantin or other anticonvulsants.

Additional advances in understanding the etiology and improving treatments for hemifacial spasm did not occur until the mid-seventies. In 1977, 47 cases of hemifacial spasm underwent microvascular decompression of the facial nerve using the operating microscope. The results illustrated nerve-vessel conflicts (or cholesteatoma) to be located at the root exit zone of the facial nerve in all cases. The root exit zone is where the central glial axonal insulation of the nerve ends and the peripheral nerve axonal myelination begins, this is known as The Obersteiner-Redlich zone. Biopsies of the root exit zone demonstrated degeneration of axons, denuded axis cylinder and interrupted myelin. The results of the experiment strengthened the theory that vascular compression of the facial nerve was the primary cause of hemifacial spasm, and proposed a specific region of the facial nerve where the effects of longstanding compression results in nerve dysfunction.

References

References

1. (2007). "Hemifacial spasm: a neurological perspective". [[Journal of Korean Neurosurgical Society]].
2. Jannetta PJ. (1998). "Typical or atypical hemifacial spasm". Journal of Neurosurgery.
3. (1998). "Atypical hemifacial spasm". Acta Neurochir.
4. Fukushima T. (1995). "Microvascular decompression for hemifacial spasm: Result in 2890 cases". McGraw Hill.
5. (2018). "Hemifacial Spasm Information Page". National Institute for Neurological Disorders and Stroke.
6. Office of Communications and Public Liaison. "NINDS Hemifacial Spasm Information Page". National Institute of Neurological Disorders and Strokes.
7. (2002). "Fully endoscopic vascular decompression of the glossopharyngeal nerve". The Journal of Craniofacial Surgery.
8. (1996). "Neuro-vascular decompression in hemifacial spasm: anatomical, electrophysiological and therapeutic results apropos of 100 cases". Rev Laryngol Otol Rhinol (Bord).
9. (2010). "Cerebellopontine angle tumors causing hemifacial spasm: types, incidence, and mechanism in nine reported cases and literature review". Acta Neurochir (Wien).
10. (1 August 2011). "The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms". Movement Disorders.
11. (1997). "Pitfalls in the diagnosis of hemifacial spasm". The Laryngoscope.
12. (1982). "Carbamazepine for hemi facial spasm". Neurology.
13. Lorentz IT. (April 1995). "Treatment of hemifacial spasm with botulinum toxin". Journal of Clinical Neuroscience.
14. (2024). "Endoscope-assisted microvascular decompression in hemifacial spasm with a teflon bridge". Acta Neurochirurgica.
15. (1984). "Treatment of tic douloureux and hemifacial spasm by posterior fossa exploration: therapeutic implications of various neurovascular relationships". Neurosurgery.
16. (1988). "Serious complications of microvascular decompression operations for trigeminal neuralgia and hemifacial spasm". Neurosurgery.
17. (November 19, 2020). "Botulinum toxin type A therapy for hemifacial spasm". The Cochrane Database of Systematic Reviews.
18. (1982). "Hemifacial spasm: treatment by microsurgical facial nerve decompression". Neurosurgery.
19. (16 January 2004). "Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30)". Journal of the Neurological Sciences.
20. (1998). "Hemifacial spasm: clinical findings and treatment". Muscle and Nerve.
21. (2002). "Hemifacial spasm and involuntary facial movements". QJM.
22. (June 2004). "Hemifacial spasm". Curr Treat Options Neurol.
23. (1990). "Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984". Arch Neurol.
24. (2006). "A comparative study of primary and secondary hemifacial spasm". Arch Neurol.
25. Wilkins RH. (1991). "Hemifacial spasm: a review". Surgical Neurology.
26. (1962). "Hemifacial Spasm - A Reversible Pathophysiologic State". Journal of Neurosurgery.
27. Jannetta PJ. (1975). "Trigeminal neuralgia and hemifacial spasm--etiology and definitive treatment". Trans Am Neurol Assoc.
28. (1977). "Etiology and definitive microsurgical treatment of hemifacial spasm. Operative techniques and results in 47 patients". Journal of Neurosurgery.